Prices of 137 Cancer Drugs Cut, NPPA Warns Against Overcharging
New Delhi: Prices of 137 non-scheduled cancer drugs have been reduced following the Centre’s decision to cap trade margins at 30%. The revised rates came into effect on November 9, with the National Pharmaceutical Pricing Authority (NPPA) directing strict compliance.
Drug manufacturers, distributors, hospitals and retailers have been asked to follow the revised prices and prominently display updated price lists. Those found overcharging will face action under the Drugs (Prices Control) Order, 2013.

So far, 85 companies have revised the maximum retail prices of 121 drugs, covering 1,366 product units. Price reductions have gone up to 96.45% for some medicines.
The Centre estimates that the move will help patients save around ₹3,541 crore, providing relief to those undergoing cancer treatment. The NPPA has also called for close monitoring to ensure that the benefits reach patients.